Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Public ClinicalTrials.gov record NCT05945823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Study identification
- NCT ID
- NCT05945823
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- Futibatinib Drug
- Pembrolizumab Drug
- Cisplatin Drug
- 5-FU Drug
- Oxaliplatin Drug
- Leucovorin Drug
- Levoleucovorin Drug
- Irinotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2023 (Actual)
- Primary completion
- Oct 1, 2026 (Estimated)
- Completion
- Jan 2027 (Estimated)
- Last update posted
- Sep 1, 2026
2023 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles UCLA - Cancer Care - Santa Monica | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Centers Midtown | Denver | Colorado | 80218 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| The Minniti Center - Medical Oncology and Hematology | Mickleton | New Jersey | 08056 | — |
| Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)) | Buffalo | New York | 14203 | — |
| NYU Langone | New York | New York | 10016 | — |
| Gabrail Cancer Center Research LLC | Canton | Ohio | 44718 | — |
| Alliance Cancer Specialists | Horsham | Pennsylvania | 19044 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Dallas VA Medical Center | Dallas | Texas | 75216 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Gundersen Lutheran Health System | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05945823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05945823 live on ClinicalTrials.gov.